HLS Therapeutics (TSE:HLS) Shares Down 0.2% - Here's Why

HLS Therapeutics Inc. (TSE:HLS - Get Free Report) shares dropped 0.2% on Wednesday . The stock traded as low as C$4.85 and last traded at C$4.87. Approximately 6,901 shares changed hands during trading, a decline of 49% from the average daily volume of 13,448 shares. The stock had previously closed at C$4.88.

Wall Street Analysts Forecast Growth

Separately, Stifel Nicolaus lifted their price target on HLS Therapeutics from C$3.50 to C$4.00 and gave the company a "hold" rating in a research report on Wednesday, March 26th.

HLS Therapeutics Stock Up 0.6%

The business has a 50-day moving average price of C$4.83 and a 200-day moving average price of C$4.39. The stock has a market cap of C$108.12 million, a PE ratio of -4.87 and a beta of 1.07. The company has a current ratio of 1.56, a quick ratio of 1.01 and a debt-to-equity ratio of 86.50.

HLS Therapeutics Company Profile

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris.